Molecular Imaging, founded in 2003 and led by president and CEO Tom Ludlam, provides in vivo preclinical imaging services to support early-stage R&D decision-making for pharmaceutical and biotechnology clients. The company has imaging and discovery expertise in oncology and inflammation and is extending its imaging efforts into other therapeutic areas. Its imaging modalities include MRI, micro-PET, bioluminescence, fluorescence (two- and three-dimensional with fluorescence molecular tomography) and micro-CT. The company operates as a specialty CRO offering contract imaging services to industry clients. The articles note a Series A financing closing, which provides growth capital to support its operations and expansion of services.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2012